Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

Nursing home patients with HIV tend to be younger. They also typically have more comorbidities than the average patient, and ...

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.

The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the body’s natural immune system as well as some therapies. A new study uses novel ...

Among patients with late diagnosed HIV infection, the choice of a two- or three-drug regimen is not associated with 48 week ...

After tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state ...

"Somebody is trusting their family member or their loved one into your hands to be a caregiver to them,” says Judi Lacinak, NP. “That's a privilege that we can't take lightly.” ...

Dr Joel Steingo of TB HIV Care says Lenacapavir could be a breakthrough in reducing infections, especially at a time when ...

Anti-HIV medications suppress the viral load of people living with HIV and provide durable protection against heterosexual transmission a study led by the University of North Carolina at Chapel Hill ...

This article, Part One of the Mercury’s Pulse Check series, was produced as a project for the USC Annenberg Center for Health ...

Cuts proposed by the Trump administration and House Republicans could drive up new HIV cases by more than 200,000 by 2030, ...

Now, the fight against HIV/AIDS is not just about governments and global health organisations anymore; it is a deeply personal one. And it is all about the choices you make, the conversations you have ...